Wednesday 05 Feb, 2025 10:14 AM
Site map | Locate Us | Login
   Tata Power Company gains after Q3 PAT rises 8% YoY to Rs 1,030 cr    Utilties shares gain    Telecom shares rise    Oil and Gas shares gain    JTL Industries rises after bagging GI pipe supply contract under Jal Jeevan Mission    Supreme Industries Ltd Slides 0.82%    Hindustan Petroleum Corporation Ltd Spurts 3.34%, BSE Oil & Gas index Gains 1.29%    RVNL bags Koratpur-Singapur road doubling project worth Rs 404 cr    Bharat Bijlee spurts after Q3 PAT soars 37% YoY to 41 crore    Thermax slides after Q3 PAT tumbles 51% YoY to Rs 116 cr    Rattanindia Ent declines on posting dismal Q3 numbers    Godrej Properties jumps after Q3 PAT soars 161% YoY    Asian Paints gains after Q3 PAT climbs 60% QoQ to Rs 1,110 cr    Thomas Cook (India) Ltd leads losers in 'A' group    Shankara Building Products Ltd leads losers in 'B' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Glenmark Pharma edges higher after US launch of coagulation disorder drug Phytonadione
21-Jan-25   10:07 Hrs IST

The aforementioned drug is bioequivalent and therapeutically equivalent to the reference listed drug Vitamin K1 Injectable Emulsion USP of Hospira, Inc.

This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.

According to IQVIA sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion market had achieved annual sales of approximately $19.7 million.

Marc Kikuchi, president & business head, North America said: We are excited to announce the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL single dose ampules, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses.

The drug maker reported consolidated net profit from continuing operations of Rs 354.49 crore in Q2 FY25 as against net loss of Rs 180.3 crore in Q2 FY24. Revenue from operations increased 2.29% year on year (YoY) to Rs 3,133.79 crore in the quarter ended 30 September 2024.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 38700734
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd